❌

Normal view

Received today β€” 7 October 2026 ⏭

SPTLC2-driven sphingolipid reprogramming of neutrophils impairs anti-tumour immunity and drives liver cancer progression

βœ‡Oncogene - Issue - nature.com science feeds
By: Zhe Yang Β· Yun Wang Β· Jianhao Li Β· Zishuo Wang Β· Jianan Chen Β· Ding Zhang Β· Guorui Zhao Β· Liwen Liu Β· Zhibo Liu Β· Ning Wang Β· Ranran Sun
28 September 2026 at 08:00

Oncogene, Published online: 28 September 2026; doi:10.1038/s41388-026-03996-2

SPTLC2-driven sphingolipid reprogramming of neutrophils impairs anti-tumour immunity and drives liver cancer progression
Received β€” 15 September 2026 ⏭

Author Correction: Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours

βœ‡Nature Biomedical Engineering
By: Qunfeng Fu Β· Shuren Zhang Β· Siyong Shen Β· Zhi Gu Β· Junyi Chen Β· Dongfan Song Β· Pengwei Sun Β· Chunhong Wang Β· Zhibin Guo Β· Yunlong Xiao Β· Yi Qin Gao Β· Zijian Guo Β· Zhibo Liu
10 September 2026 at 08:00

Nature Biomedical Engineering, Published online: 10 September 2026; doi:10.1038/s41551-026-01810-8

Author Correction: Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours
There are no more articles
❌